TrialJournal for immunotherapy of cancer2024

Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).

Ulka N Vaishampayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.